Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non-Insulin-Dependency: An Open-Label Randomized…

Overview of attention for article published in Diabetes Therapy, September 2017

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (52nd percentile)
Above-average Attention Score compared to outputs of the same age and source (54th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 41 Dimensions

Readers on

mendeley: 38 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 7,863 followers.

@gliflozin @OdaQ_DM おっしゃる通り、TOKYO StudyのSUvsインスリンの結果と、SPAN-SなどDPP4i vs SU等の結果によると思います。 https://t.co/Grv0hsmuCD https://t.co/lxndhqzo5t https://t.co/QYw9kK1xFo https://t.co/JK4VTaxjl2

13 Jan 2024

Reply Repost Favourite

@fireneurologist 自分が読んだことあるのはこれです。これ以外知らないので諸説あったらすいません。話のネタくらいにはなるかなと思います。 https://t.co/FZxhVcKMTl

30 Jun 2023

Reply Repost Favourite

RT @BaikinDr: Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDD…

23 Jan 2020

Reply Repost Favourite

Possible Long-Term Efficacy of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, for Slowly Progressive Type 1 Diabetes (SPIDDM) in the Stage of Non... - PubMed - NCBI https://t.co/83Ws2VOpvd SPIDDMに対してはインスリンよりもシタグリプチンを使用した方がβ細胞長持ちする

23 Jan 2020

Reply Repost Favourite